Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity

W. Wulaningsih, H. Garmo, J. Ahlgren, L. Holmberg, Y. Folkvaljon, A. Wigertz, M. Van Hemelrijck, M. Lambe

Abstract

Purpose To examine factors associated with non-adherence during 5 years of endocrine treatment, including the possible influence of comorbidity burden and specific medical conditions.

Methods From all women diagnosed with stage I–III, ER-positive breast cancer in Stockholm-Gotland, Uppsala–Örebro and Northern Sweden between 2006 and 2009, we included 4645 women who had at least one dispensation of tamoxifen or aromatase inhibitors (AIs) and 5 years of follow-up without distant recurrence. A medical possession ratio of < 80% was used to define non-adherence. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of non-adherence.

Results During follow-up, 977 (21%) women became non-adherents. Non-adherence was associated with greater comorbidity burden assessed by Charlson comorbidity index (CCI) during follow-up (OR 1.43; 95% CI 1.08–1.88 for ≥ 2 additional scores compared to 0), pre-diagnostic HRT use (OR 1.99; 1.58–2.49), not married (OR 1.42; 1.23–1.64), high educational level (OR 1.25; 1.02–1.53 compared to lowest level), and use of symptom-relieving drugs. HER-2 positivity (OR 0.61; 0.45–0.81) and adjuvant chemotherapy (OR 0.42; 0.35–0.52) were associated with lower odds of non-adherence. Similar patterns were observed for the presence of lymph node metastasis, higher tumour grade, and use of AIs compared to tamoxifen. Myocardial infarction and chronic pulmonary disease was suggested as leading conditions associated with non-adherence in women with increasing CCI.

Conclusion We identified subgroups of women with breast cancer at increased risk of non-adherence. Our findings related to comorbidity suggest the importance of focusing on the presence of specific co-existing conditions when monitoring adherence.

Keywords Breast cancer • Endocrine treatment • Adherence • Tamoxifen • Comorbidity

Background

Adjuvant endocrine treatment (ET) is part of the standard therapy for oestrogen receptor (ER)-positive breast cancers [1]. Survival benefit following an extended use of ET has been documented,[2] prompting recommendation for 5–10 years use of ET following a breast cancer diagnosis [3]. On the other hand, low adherence to adjuvant ET in breast cancer may result in shorter time to recurrence, higher medical costs and poorer quality of life [4, 5]. Therefore, an improved understanding of factors affecting patient adherence is of importance when developing intervention strategies. A systematic review including 30 studies investigating non-adherence and/or discontinuation of ET in women with hormone receptor-positive breast cancer have...
suggested several key determinants, including patient age, out-of-pocket costs, changes of therapy, follow-up and treatment side effects [6, 7]. However, these studies differed with regard to assessment methods, length of follow-up and factors under study [6, 8]. Furthermore, while findings from earlier studies have linked multimorbidity with lower adherence to ET [9], results from most studies have been based on comorbidities assessed at baseline and did not investigate specific types of co-existing disease or changes in comorbidity burden over time.

We have previously reported on non-adherence and early discontinuation patterns of use of adjuvant endocrine treatment among women with breast cancer in Sweden [10]. Following an update of the cohort used in that study, we aimed to further investigate determinants of adherence by extending duration of follow-up to 5 years, and including additional potential determinants ranging from patient to health system-related factors based on the World Health Organization (WHO) multidimensional model for drug adherence [11]. In addition, we assessed the possible influence of comorbidities both quantitatively and qualitatively by looking into specific conditions.

Methods

Study population

Our study was based on information in the breast cancer research database BCBaSe generated by record linkage between four Swedish population-based registers. Details on period and data covered by each register are shown in Fig. 1. The Regional Breast Cancer Clinical Quality Registers of the Uppsala/Örebro, Stockholm-Gotland and Northern regions of Sweden includes information on women newly diagnosed with breast cancer in these regions with less than 5% missing when validated against the National Swedish Cancer Register to which reporting is mandated. The Swedish Prescribed Drug Register encompasses prescribed medications dispensed in Swedish pharmacies and includes information on dates of dispensation, number of defined daily doses (DDD) and classification of the drugs based on the Anatomic Therapeutic Chemical (ATC) system. Individual-level information on socioeconomic and demographic factors was obtained from the Longitudinal

Fig. 1  Data sources. Each rectangle illustrates different Swedish registers which were cross-linked using an individually unique 10-digit personal identification number to generate the research database BCBaSe. Shaded area indicates the period of observation between 2005 and 2014 which the present study was based on. Patient Registers: diagnostic codes for inpatient and outpatient care. BC Quality Registry: Regional Breast Cancer Clinical Quality Registers of the Uppsala/Örebro, Stockholm-Gotland and Northern regions of Sweden. LISA register: Longitudinal integration database for health insurance and labour market studies. Prescribed Drug Register: details regarding filed drugs
integration database for health insurance and labour market studies (LISA) that integrates existing data from labour market-, educational-, and social-sector registers on all individuals 16 years or older residing in Sweden, and is updated on a yearly basis. Finally, the Swedish Patient Register contains information on hospital admissions and outpatient clinic visits with dates and diagnostic codes. Information from the above registers was linked using a ten-digit personal identifier number assigned to all permanent residents in Sweden.

Study population and follow-up

We identified all women residing in the Uppsala/Örebro, Stockholm-Gotland and Northern regions of Sweden with a diagnosis of stage I–III ER-positive invasive breast cancer between July 1, 2006 and June 30, 2009 and at least one dispensation of oral tamoxifen (ATC code: L02BA01) or aromatase inhibitor (AI; anastrozole, exemestane, or letrozole; ATC code: L02BG) after diagnosis (Fig. 2). To avoid misclassification of adherence status because of early death and metastasis, women who died or had distant metastasis during follow-up were excluded (Fig. 1). We used a run-in period of 6 months to avoid overestimation of adherence to endocrine treatment [12]. This 6-month interval was based on the median duration between breast cancer diagnosis and the initial dispensation of endocrine treatment. Therefore, for all women, follow-up started at the end of run-in period, i.e. 6 months post-diagnosis, and ended 5 years afterwards.

Adherence to endocrine treatment

Patterns of adherence were assessed based on tamoxifen and AI dispensations as recorded in the Swedish Prescribed Drug Register. To quantify adherence to endocrine treatment, we calculated medical possession ratio (MPR) as the ratio of the number of days for which a patient has medication on hand divided by the total number of days of follow-up, and multiplied by 100%. Non-adherence was defined as having an MPR of < 80%.

Determinants of adherence

We classified potential determinants of adherence based on the World Health Organization (WHO) multidimensional adherence model (Fig. 3) [11]. Five major factors were considered to influence adherence: socioeconomic, patient-related, condition-related, therapy-related and health system-related factors.

For the purpose of the present study, health system-related factors included region where breast cancers were diagnosed and whether surgery or follow-up was conducted in university hospitals.

Patient-related factors included age at diagnosis, educational level, menopausal status, marital status, comorbidities and prior medications. Educational attainment was categorised into low, medium and high, corresponding to less than high school (≤ 9 years), high school graduate (10–12 years) and higher education (> 12 years), respectively.

Comorbidities were assessed by calculating the Charlson comorbidity index (CCI) [13] based on information on inpatient admissions and outpatient visits 10 years
prior to the start of follow-up and data on specific medications (e.g. insulin for diabetes) prescribed during the run-in period. The CCI consists of 17 groups of diseases with a specific weight assigned to each condition, and these weights were then summed to obtain an overall score, resulting in four comorbidity levels (0, 1, 2 and 3+) indicating no comorbidity to severe comorbidity. In addition to CCI assessed at baseline, we also calculated CCI at the end of follow-up and any differences between the two continuous scores (ΔCCI) were estimated.

We collected information on drugs commonly associated with adverse effects of cancer treatments. Included in this category were analgesics (ATC code: N02), hypnotics or sedatives (ATC code: N05C), antidepressants (ATC code: N06A), gastrointestinal (GI) drugs (ATC code: A02–A07) and topical oestrogen for vaginal use (ATC code: G03C). Use of these drugs was calculated during the run-in period to assess baseline use, and during follow-up using information from the Prescribed Drug Register. Baseline use of oral hormone replacement therapy (HRT; ATC code: G03C–G03F) was collected since 1 year prior to breast cancer diagnosis until the end of the run-in period. Drugs used during follow-up may reflect adverse effect of cancer treatment and, therefore, they were classified under treatment-related factors. Other treatment-related factors were type of primary surgery, radiotherapy, chemotherapy and type of endocrine treatment used.

Condition-related factors included tumour size, lymph node involvement, tumour grade based on Elston grading system, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status.

Statistical analysis

Univariable logistic regression analysis was performed to estimate odds ratios (OR) and their 95% confidence intervals (CI) of non-adherence to ET for each potential determinant, with women who remained adherent as the reference group. Analyses were repeated following adjustment of age at baseline, and a further analysis was conducted while additionally adjusting for SES. A sensitivity analysis was performed by excluding women without records of any dispensation of ET during the final year of follow-up, representing those who discontinued treatment. To tease out the potential role of specific medical conditions for a given comorbidity group in CCI, Fisher’s exact test was used to assess differences in the proportion of non-adherents by whether women never had, or had the condition at baseline, or were diagnosed with the specific co-existing disease during follow-up.

Results

A total of 4645 women with ER-positive breast cancers treated with ET were included in our analysis. During the 5-year follow-up, 977 women (21%) became non-adherent, i.e. having MPR < 80%. Table 1 describes study participants by adherence status and potential determinants of non-adherence, and the corresponding estimates from regression analysis. The majority of women were postmenopausal and had completed high school. In univariable analyses, we identified several predictors of non-adherence to ET.

Patient-related factors

The likelihood of non-adherence increased with older age (OR 1.23, 95% CI 1.05–1.43 for age 65 and older compared to 50–64), an increase in the comorbidity burden during and at the end of 5-year observation (e.g. OR 1.54, 95% CI 1.17–2.01 for gain of 2 or more in CCI compared to 0 during follow-up), prior use of HRT (OR 1.86, 95% CI 1.48–2.32), use of analgesics (OR 1.17, 95% CI 1.00–1.37) or hypnotics and sedatives (OR 1.39, 95% CI 1.15–1.68) at baseline. Use of GI drugs at baseline was inversely associated with non-adherence (OR 0.68, 95% CI 0.56–0.82). Following adjustment for age, associations remained for increases in CCI during follow-up, prior HRT use, use of hypnotics and sedatives and GI drugs at baseline (Table 1). Further adjustment for education did not alter these results.

Socioeconomic factors

There were differences in ET adherence across indicators of socioeconomic standing as reflected by greater odds of non-adherence by non-married/single status (unmarried versus married age-adjusted OR 1.42, 95% CI 1.23–1.64). Also, the likelihood of non-adherence was elevated in women with high compared to low educational level (age-adjusted OR 1.25, 95% CI 1.02–1.53), an association that remained virtually unchanged following adjustments for tumour size, presence of lymph node metastasis and pre-diagnostic use of HRT (data not shown).

Health system factors

While there was evidence of regional variations with the lowest odds of non-adherence observed in Northern Sweden (age-adjusted OR 0.58, 95% CI 0.45–0.73), no differences were observed between university hospitals and
Table 1: Determinants of non-adherence to adjuvant endocrine treatment in Swedish women diagnosed with ER-positive breast cancers, stage I–III between 1 July 2006 and 30 June 2009

| Characteristics                              | Adherent (N = 3 668) | Non-adherent (N = 977) | OR (95% CI) | Unadjusted | Adjusted for age | Adjusted for age and education |
|---------------------------------------------|----------------------|------------------------|-------------|------------|------------------|------------------------------|
| Patient-related                             |                      |                        |             |            |                  |                              |
| Age at diagnosis (years)                    |                      |                        |             |            |                  |                              |
| < 50                                        | 685                  | 18.7                   | 186         | 19.0       | 1.13 (0.93–1.37) | –                            |
| 50–64                                       | 1630                 | 44.4                   | 392         | 40.1       | 1.0 (Ref)        |                              |
| ≥ 65                                        | 1353                 | 36.9                   | 399         | 40.8       | 1.23 (1.05–1.43) |                              |
| Menopausal status                           |                      |                        |             |            |                  |                              |
| Premenopausal                               | 723                  | 19.7                   | 196         | 20.1       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Postmenopausal                              | 2610                 | 71.2                   | 714         | 73.1       | 1.01 (0.85–1.21) | 1.27 (0.94–1.72)             | 1.28 (0.95–1.73)             |
| Unknown                                     | 335                  | 9.1                    | 67          | 6.9        | –                | –                            | –                            |
| Baseline CCI                                |                      |                        |             |            |                  |                              |
| 0                                          | 3121                 | 85.1                   | 809         | 82.8       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| 1                                          | 355                  | 9.7                    | 108         | 11.1       | 1.17 (0.93–1.47) | 1.14 (0.90–1.43)             | 1.15 (0.90–1.44)             |
| 2                                          | 130                  | 3.5                    | 36          | 3.7        | 1.07 (0.72–1.54) | 0.98 (0.66–1.43)             | 0.99 (0.67–1.44)             |
| 3+                                         | 62                   | 1.7                    | 24          | 2.5        | 1.49 (0.91–2.37) | 1.37 (0.83–2.20)             | 1.40 (0.85–2.24)             |
| FU CCI                                     |                      |                        |             |            |                  |                              |
| 0                                          | 2650                 | 72.2                   | 647         | 66.2       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| 1                                          | 553                  | 15.1                   | 180         | 18.4       | 1.33 (1.10–1.61) | 1.30 (1.07–1.58)             | 1.31 (1.08–1.59)             |
| 2                                          | 277                  | 7.6                    | 86          | 8.8        | 1.27 (0.98–1.64) | 1.21 (0.92–1.57)             | 1.22 (0.93–1.58)             |
| 3+                                         | 188                  | 5.1                    | 64          | 6.6        | 1.39 (1.03–1.87) | 1.29 (0.94–1.74)             | 1.30 (0.95–1.76)             |
| Increase in CCI                             |                      |                        |             |            |                  |                              |
| 0                                          | 3021                 | 82.4                   | 767         | 78.5       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| 1                                          | 440                  | 12.0                   | 129         | 13.2       | 1.15 (0.93–1.42) | 1.10 (0.88–1.37)             | 1.11 (0.89–1.37)             |
| 2+                                         | 207                  | 5.6                    | 81          | 8.3        | 1.54 (1.17–2.01) | 1.43 (1.08–1.88)             | 1.43 (1.08–1.88)             |
| Prediagnostic HRT                           |                      |                        |             |            |                  |                              |
| No                                         | 3393                 | 92.5                   | 849         | 86.9       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Yes                                        | 275                  | 7.5                    | 128         | 13.1       | 1.86 (1.48–2.32) | 1.99 (1.58–2.49)             | 1.98 (1.58–2.48)             |
| Baseline analgesics                         |                      |                        |             |            |                  |                              |
| No                                         | 2748                 | 74.9                   | 702         | 71.9       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Yes                                        | 920                  | 25.1                   | 275         | 28.1       | 1.17 (1.00–1.37) | 1.16 (0.99–1.36)             | 1.17 (1.00–1.37)             |
| Baseline hypnotics and sedatives            |                      |                        |             |            |                  |                              |
| No                                         | 3189                 | 86.9                   | 808         | 82.7       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Yes                                        | 479                  | 13.1                   | 169         | 17.3       | 1.39 (1.15–1.68) | 1.38 (1.14–1.67)             | 1.37 (1.13–1.66)             |
| Baseline antidepressants                    |                      |                        |             |            |                  |                              |
| No                                         | 3301                 | 90.0                   | 868         | 88.8       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Yes                                        | 367                  | 10.0                   | 109         | 11.2       | 1.13 (0.90–1.41) | 1.13 (0.90–1.42)             | 1.13 (0.90–1.42)             |
| Baseline GI drugs                           |                      |                        |             |            |                  |                              |
| No                                         | 2928                 | 79.8                   | 834         | 85.4       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Yes                                        | 740                  | 20.2                   | 143         | 14.6       | 0.68 (0.56–0.82) | 0.68 (0.55–0.83)             | 0.68 (0.55–0.83)             |
| Baseline vaginal oestrogen                  |                      |                        |             |            |                  |                              |
| No                                         | 3577                 | 97.5                   | 948         | 97.0       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Yes                                        | 91                   | 2.5                    | 29          | 3.0        | 1.20 (0.77–1.81) | 1.18 (0.75–1.78)             | 1.17 (0.75–1.78)             |
| Socioeconomic factors                       |                      |                        |             |            |                  |                              |
| Marital status                              |                      |                        |             |            |                  |                              |
| Married                                     | 2008                 | 54.7                   | 437         | 44.7       | 1.0 (Ref)        | 1.0 (Ref)                    | 1.0 (Ref)                    |
| Single/divorced/widowed                     | 1656                 | 45.1                   | 539         | 55.2       | 1.50 (1.30–1.72) | 1.42 (1.23–1.64)             | 1.42 (1.23–1.64)             |
| Unknown                                     | 4                    | 0.1                    | 1           | 0.1        | –                | –                            | –                            |
Table 1 (continued)

| Characteristics                          | Adherent (N = 3 668) | Non-adherent (N = 977) | OR (95% CI) |
|-----------------------------------------|----------------------|------------------------|-------------|
|                                         | No. %                | No. %                  | Unadjusted  | Adjusted for age | Adjusted for age and education |
| Education                               |                      |                        |             |                  |                                     |
| Low                                     | 900 24.5 225 23.0    | 1.0 (Ref)              | 1.0 (Ref)   | –                 | –                                    |
| Medium                                  | 1503 41.0 399 40.8   | 1.06 (0.88–1.28)       | 1.17 (0.97–1.42) | –                 | –                                    |
| High                                    | 1241 33.8 345 35.3   | 1.11 (0.92–1.34)       | 1.25 (1.02–1.53) | –                 | –                                    |
| Unknown                                 | 24 0.7 8 0.8         | –                      | –           | –                 | –                                    |
| Health system related                   |                      |                        |             |                  |                                     |
| Region                                  |                      |                        |             |                  |                                     |
| Stockholm–Gotland                       | 1376 37.5 446 45.6   | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| Uppsala–Örebro                          | 1751 47.7 431 44.1   | 0.76 (0.65–0.88)       | 0.74 (0.64–0.86) | 0.75 (0.64–0.87) |                                     |
| Northern Sweden                         | 541 14.7 100 10.2    | 0.57 (0.45–0.72)       | 0.58 (0.45–0.73) | 0.59 (0.46–0.74) |                                     |
| Hospital type for surgery               |                      |                        |             |                  |                                     |
| University hospital                     | 1004 27.4 244 25.0   | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| Other hospitals                         | 2655 72.4 732 74.9   | 1.13 (0.97–1.34)       | 1.12 (0.95–1.32) | 1.12 (0.96–1.32) |                                     |
| Unknown                                 | 9 0.2 1 0.1          | –                      | –           | –                 | –                                    |
| Hospital type for follow-up             |                      |                        |             |                  |                                     |
| University hospital                     | 1452 39.6 360 36.8   | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| Other hospitals                         | 2007 54.7 548 56.1   | 1.10 (0.95–1.28)       | 1.12 (0.96–1.30) | 1.12 (0.97–1.30) |                                     |
| Unknown                                 | 209 5.7 69 7.1       | –                      | –           | –                 | –                                    |
| Disease-related                         |                      |                        |             |                  |                                     |
| Tumour size (mm)                        |                      |                        |             |                  |                                     |
| < 20                                    | 2255 61.5 686 70.2   | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| 20–50                                   | 1208 32.9 261 26.7   | 0.71 (0.61–0.83)       | 0.65 (0.55–0.77) | 0.65 (0.56–0.77) |                                     |
| ≥ 50                                    | 126 3.4 18 1.8       | 0.47 (0.28–0.75)       | 0.43 (0.25–0.70) | 0.44 (0.25–0.70) |                                     |
| Unknown                                 | 79 2.2 12 1.2        | –                      | –           | –                 | –                                    |
| Lymph node metastasis                   |                      |                        |             |                  |                                     |
| No                                      | 3103 84.6 883 90.4   | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| Yes                                     | 534 14.6 79 8.1      | 0.52 (0.40–0.66)       | 0.51 (0.39–0.65) | 0.51 (0.40–0.65) |                                     |
| Unknown                                 | 31 0.8 15 1.5        | –                      | –           | –                 | –                                    |
| Tumour grade                            |                      |                        |             |                  |                                     |
| I                                       | 827 22.5 289 29.6    | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| II                                      | 2022 55.1 511 52.3   | 0.72 (0.61–0.85)       | 0.70 (0.59–0.83) | 0.70 (0.59–0.83) |                                     |
| III                                     | 747 20.4 156 16.0    | 0.60 (0.48–0.74)       | 0.58 (0.47–0.73) | 0.58 (0.47–0.73) |                                     |
| Unknown                                 | 72 2.0 21 2.1        | –                      | –           | –                 | –                                    |
| PR status                               |                      |                        |             |                  |                                     |
| Pr−                                     | 659 18.0 167 17.1    | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| Pr+                                     | 2988 81.5 806 82.5   | 1.06 (0.89–1.29)       | 1.05 (0.88–1.28) | 1.06 (0.88–1.29) |                                     |
| Unknown                                 | 21 0.6 4 0.4         | –                      | –           | –                 | –                                    |
| HER2 status                             |                      |                        |             |                  |                                     |
| Her2−                                   | 2772 75.6 725 74.2   | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| Her2+                                   | 344 9.4 55 5.6       | 0.61 (0.45–0.82)       | 0.61 (0.45–0.81) | 0.61 (0.45–0.82) |                                     |
| Unknown                                 | 552 15.0 197 20.2    | –                      | –           | –                 | –                                    |
| Treatment-related                       |                      |                        |             |                  |                                     |
| Type of primary surgery                 |                      |                        |             |                  |                                     |
| Sector resection                        | 2325 63.4 659 67.5   | 1.0 (Ref)              | 1.0 (Ref)   | 1.0 (Ref)         |                                     |
| Mastectomy                              | 1281 34.9 304 31.1   | 0.84 (0.72–0.97)       | 0.75 (0.64–0.87) | 0.75 (0.64–0.87) |                                     |
| Other types                             | 7 0.2 5 0.5          | 2.52 (0.74–7.92)       | 2.51 (0.74–7.92) | 2.48 (0.73–7.84) |                                     |
other types of hospitals. Results remained unchanged following adjustment for education (Table 1).

### Disease-related factors

The presence of lymph node metastasis (OR 0.52, 95% CI 0.40–0.66), higher tumour grade (e.g. OR 0.60, 95% CI 0.48–0.74 for grade III compared to I) and HER2-positive tumours (OR 0.61, 95% CI 0.45–0.82) were associated with lower odds of non-adherence to ET. These associations remained following adjustment for age and education (Table 1).

### Treatment

We found lower odds of non-adherence in women undergoing mastectomy and in women without a record of surgery (n = 55) compared to sector resection (age-adjusted OR 0.75, 95% CI 0.64–0.87 and 0.43, 95% CI 0.16–0.94, respectively), use of AI or both AI and tamoxifen compared to tamoxifen only (age-adjusted OR 0.72, 95% CI 0.58–0.89

---

### Table 1 (continued)

| Characteristics                  | Adherent (N = 3668) | Non-adherent (N = 977) | OR (95% CI) |
|----------------------------------|---------------------|------------------------|-------------|
|                                  | No. | %    | No. | %    | Unadjusted | Adjusted for age | Adjusted for age and education |
| Not operated                     | 49  | 1.3  | 6   | 0.6  | 0.43 (0.17–0.94) | 0.43 (0.16–0.94) | 0.43 (0.17–0.94) |
| Unknown                          | 6   | 0.2  | 3   | 0.3  | –           | –             | –                      |
| Radiotherapy                     |      |      |     |      |             |               |                         |
| No                               | 1021 | 27.8 | 309 | 31.6 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 2647 | 72.2 | 668 | 68.4 | 0.83 (0.72–0.97) | 0.95 (0.80–1.12) | 0.94 (0.80–1.12) |
| Adjuvant chemotherapy            |      |      |     |      |             |               |                         |
| No                               | 2577 | 70.3 | 824 | 84.3 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 1091 | 29.7 | 153 | 15.7 | 0.44 (0.36–0.53) | 0.42 (0.35–0.52) | 0.43 (0.35–0.52) |
| Type of endocrine treatment      |      |      |     |      |             |               |                         |
| Tamoxifen only                   | 1805 | 49.2 | 536 | 54.9 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| AI only                          | 640  | 17.4 | 138 | 14.1 | 0.73 (0.59–0.89) | 0.72 (0.58–0.89) | 0.72 (0.58–0.89) |
| Tamoxifen + AI                   | 1223 | 33.3 | 303 | 31.0 | 0.83 (0.71–0.98) | 0.85 (0.73–1.00) | 0.86 (0.73–1.01) |
| First endocrine treatment        |      |      |     |      |             |               |                         |
| Tamoxifen                        | 757  | 61.9 | 221 | 72.9 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| AI                               | 466  | 38.1 | 82  | 27.1 | 0.60 (0.45–0.79) | 0.54 (0.41–0.72) | 0.54 (0.41–0.72) |
| ET switch                        |      |      |     |      |             |               |                         |
| No                               | 2445 | 66.7 | 674 | 69.0 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 1223 | 33.3 | 303 | 31.0 | 0.90 (0.77–1.05) | 0.93 (0.79–1.08) | 0.93 (0.80–1.09) |
| FU analgesics                    |      |      |     |      |             |               |                         |
| No                               | 2040 | 55.6 | 450 | 46.1 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 1628 | 44.4 | 527 | 53.9 | 1.47 (1.27–1.69) | 1.41 (1.22–1.63) | 1.43 (1.24–1.66) |
| FU hypnotics and sedatives       |      |      |     |      |             |               |                         |
| No                               | 2712 | 73.9 | 634 | 64.9 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 956  | 26.1 | 343 | 35.1 | 1.53 (1.32–1.78) | 1.50 (1.28–1.75) | 1.49 (1.28–1.74) |
| FU antidepressants               |      |      |     |      |             |               |                         |
| No                               | 2852 | 77.8 | 713 | 73.0 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 816  | 22.2 | 264 | 27.0 | 1.29 (1.10–1.52) | 1.27 (1.08–1.49) | 1.27 (1.08–1.50) |
| FU GI drugs                      |      |      |     |      |             |               |                         |
| No                               | 2932 | 79.9 | 726 | 74.3 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 736  | 20.1 | 251 | 25.7 | 1.38 (1.17–1.62) | 1.30 (1.10–1.54) | 1.31 (1.10–1.55) |
| FU vaginal oestrogen             |      |      |     |      |             |               |                         |
| No                               | 3261 | 88.9 | 836 | 85.6 | 1.0 (Ref)  | 1.0 (Ref)     | 1.0 (Ref)              |
| Yes                              | 407  | 11.1 | 141 | 14.4 | 1.35 (1.10–1.66) | 1.34 (1.08–1.65) | 1.33 (1.08–1.64) |

OR, odds ratio; CI, confidence interval; FU, follow-up; AI, aromatase inhibitors; GI, gastro-intestinal.
and 0.85, 95% CI 0.73–1.00, respectively), starting out ET with AI rather than tamoxifen (age-adjusted OR 0.54, 95% CI 0.41–0.72), and in women receiving adjuvant chemotherapy (age-adjusted OR 0.42 95% CI 0.35–0.52).

Compared to non-users, odds of non-adherence were elevated in women using hypnotics and sedatives (age- adjusted OR 1.50, 95% CI 1.28–1.75), antidepressants (age-adjusted OR 1.27, 95% CI 1.08–1.49), GI drugs (age-adjusted OR 1.30, 95% CI 1.10–1.54) and vaginal oestrogens (age-adjusted OR 1.34, 95% CI 1.08–1.65) during follow-up. These associations remained following adjustment for education (Table 1). Results were similar, albeit weaker when women without ET dispensation during the final year of follow-up were excluded (data not shown).

**Comorbidity burden**

In a final step, we assessed whether non-adherence varied between women who did not have a specific co-existing medical condition, those who had the comorbidity prior to treatment, and women diagnosed with the condition during follow-up. These analyses were repeated for all disease entities included in the CCI domain, and results for the ten major comorbidities are shown in Table 2. The most common co-existing conditions observed included chronic pulmonary disease, cardiovascular disease and diabetes. Non-adherence was more common in women with a first record of chronic pulmonary disease during follow-up (44 out of 141 women were non-adherent = 31%) compared to those who never had it (21%) or were diagnosed with the condition before start of ET (22%), with significant differences demonstrated by Fisher’s exact test ($P = 0.01$). A higher proportion of non-adherent women ($P = 0.007$) was also observed in those diagnosed with myocardial infarction (MI) during follow-up (37%) compared to women without a history of MI (21%) or with a record of MI before ET (33%). No difference in the proportion of non-adherence was observed across women who had diabetes before diagnosis, during follow-up, or those without the condition.

**Discussion**

In Swedish women undergoing adjuvant endocrine treatment for ER-positive non-metastatic breast cancer, we found a broad range of factors associated with non-adherence to ET including age, region, increases in comorbidity burden, marital status, educational level, use of HRT and symptom-relieving drugs, tumour characteristics, adjuvant chemotherapy and type of ET.

While we found no strong association between younger age and non-adherence to ET, our results support earlier evidence of lower adherence in both younger and older age groups [6, 7]. It has been suggested that not only treatment side effects, but also fertility concerns contribute to low adherence and discontinuation in young (<45 years) women [14]. In older age groups, multi-morbidity has been suggested to explain lower rates of adherence [15]. Few studies to date have addressed the possible role of specific comorbidities on adherence to ET. In the present study, we found evidence of higher odds of non-adherence in women among whom the comorbidity burden increased during follow-up, particularly chronic pulmonary disease and myocardial infarction. Interestingly, long-term use of cardiovascular drugs, i.e. antihypertensives and statins has been linked to greater adherence, [16] whereas non-adherence to chronic

| Table 2 Non-adherence across prevalence of ten leading co-morbidities | N non-adherent/N adherent | $P$ value* |
|---|---|---|
| | Never | At baseline | During follow-up |
| Chronic pulmonary disease | 881/3377 | 55/191 | 44/97 | 0.01 |
| Cerebrovascular disease | 907/3459 | 40/108 | 33/98 | 0.09 |
| Diabetes without complications | 908/3405 | 49/161 | 23/99 | 0.62 |
| Congestive heart failure | 937/3535 | 18/56 | 25/74 | 0.43 |
| Connective tissue and rheumatic disease | 945/3555 | 19/72 | 16/38 | 0.30 |
| Myocardial infarction | 949/3607 | 14/29 | 17/29 | 0.007 |
| Diabetes with complications | 960/3606 | 12/36 | 8/23 | 0.59 |
| Other cancer(s) | 960/3583 | 20/82 | 0/0 | 0.81 |
| Dementia | 960/3611 | 4/10 | 16/44 | 0.40 |
| Peripheral vascular disease | 964/3606 | 10/24 | 6/35 | 0.32 |
| Peptic ulcer disease | 965/3614 | 2/23 | 13/28 | 0.07 |
| Renal disease | 967/3627 | 5/12 | 8/26 | 0.55 |
| Paraplegia and hemiplegia | 970/3642 | 4/10 | 6/13 | 0.33 |
| Moderate or severe liver disease | 978/3656 | 1/3 | 1/6 | 0.99 |

*Fisher’s exact $P$ value
medications including cardiovascular drugs was associated with non-adherence to ET [17]. Taken together, these findings point to complex associations between specific age-related comorbidities, poly-pharmacy and adherence to ET.

We found that women with a previous history of HRT use were less likely to adhere to ET. Earlier findings indicate that HRT use is associated with an increased risk of adverse effects from ET [18, 19], possibly reflecting withdrawal effects from discontinuation of HRT that add to side effects from ET. An alternative explanation is that women with a previous history of HRT use, on a group level are more prone to develop postmenopausal symptoms as side effects from ET. Or it could be a combination of these two suggested mechanisms.

Chemotherapy preceding ET was associated with better adherence, a finding that may be explained by a more advanced tumour stage and a high motivation to remain adherent.

We also found associations between use of hypnotics and sedatives both at baseline and during follow-up, and non-adherence to ET, possibly reflecting that quality of life influences the likelihood to use ET as prescribed. However, further research is needed to confirm the direction of this association.

In part, the present results support previous evidence of a role of socioeconomic factors as predictors of non-adherence to ET [6]. Our finding of an association between being unmarried or living alone and poorer adherence may be mediated by low social support [20]. We found minor differences in adherence between educational groups; if anything, the likelihood of non-adherence was elevated in women with the highest compared to low education. In previous studies, low adherence in low-income populations have been reported [21, 22]. A US-based study on patterns of use of AIs within 1 year of start of treatment found that high out-of-pocket prescription costs negatively affected adherence in commercially insured women with breast cancer [23] in Sweden, there is a cap limitation on out-of-pocket cost for medication, which may explain the lack of an association in our study between low education and non-adherence. Our finding of an elevated risk of non-adherence in the group of women with the highest education is difficult to explain, but may reflect informed patient decision-making regarding risk versus benefits of adjuvant endocrine therapy.

We found some evidence of regional differences in adherence proportions. Regional differences may reflect variation in patterns of breast cancer management [24] including follow-up, repeat visits and counselling. Despite the existence of Swedish national guidelines for breast cancer management, reports from the National Breast Cancer Quality Register have documented regional differences in some dimensions of provision of breast cancer care [25]. In a recent register-based study conducted in three counties in Southern Sweden, all with systems of yearly follow-up of women prescribed ET, non-adherence was considerably lower than that observed in our study [12]. It is of importance to clarify which specific components of provider counselling and follow-up that improve adherence to ET.

We found that women that had undergone mastectomy, and those without a history of surgery, were less likely to be non-adherent compared to sector resected women. In women undergoing mastectomy, a more advanced tumour stage may explain an adherent medication-taking behaviour, in particular, since we also found evidence of better adherence in patients with large tumour size and grade, or lymph node metastasis. On the other hand, in women not undergoing surgery, ET may be the only treatment, for instance, elderly and/or frail women. Thus, a low rate of non-adherence in this group of women could reflect a high motivation to use ET in the absence of other treatments.

We did not have information on subjective patient-related factors which may influence the decision-making on ET [26]. Among these factors, concerns of adverse effects have been reported to be correlated with ET discontinuation [27]. Patient decision-making occurs not only prior to initiation of ET, but also during treatment [28]. This may indicate that information regarding ET benefits and implications needs to be communicated not only at start of treatment, but also at repeat visits or follow-up contacts. However, results from a recent systematic review indicate that behavioural interventions aimed to improve adherence through patient education and follow-up reminders were unable to demonstrate any benefit [29]. Taken together, these findings indicate that improvement of ET adherence requires comprehensive approaches involving determinants beyond patient-dependent factors.

Strengths of our study included the population-based setting covering three Swedish health care regions. Individual level information was available for a broad range of potential determinants spanning from patient-related to health system-related factors. In contrast to many prior studies based on short follow-up periods, we were able to assess adherence during a 5-year period for all women. Furthermore, the availability of information on comorbidity added to prior evidence by pointing to a possible role of specific medical conditions that increase the likelihood of non-adherence to ET.

Several limitations need mentioning. We measured adherence by drug dispensation/filings of prescriptions rather than by actual use, which may result in misclassification. However, direct measurements of drug use is costly, and bias has also been reported with other indirect measures such as patient self-report and pill count, especially in patient with chronic diseases [30]. Combination of indirect measures of adherence, such as pharmacy data used in this study, has been shown to correlate better with clinical outcomes.
compared to individual level measures, [31] but its feasibility is unclear especially in the context of cancer.

Also, we were unable to explore the possible influence of psychological factors. However, we assessed associations between use of hypnotics, sedatives and antidepressants and non-adherence. Additionally, using objective measures of factors affecting adherence have been recommended instead of patient-centred measures which tend to stigmatisate women as solely responsible for being non-adherent [32]. Future research also needs to investigate the causality of the observed associations to identify points of intervention to improve adherence.

Conclusion

We conclude that predictors of non-adherence to ET extend beyond patient-related factors, supporting the notion that aspects of medication taking behaviours need to be addressed in a multidimensional fashion. Subgroups of women more likely to be non-adherent may benefit from tailored information on treatment benefit and risks, monitoring and repeated counselling throughout the planned course of endocrine treatment. Prospective studies are needed to determine the benefit of specific components of interventions to improve adherence.

Acknowledgements This project was made possible by the work of the steering group of the National Breast Cancer Register of Sweden.

Funding This study was funded by Swedish Cancer Society (2012/804).

Compliance with ethical standards

Conflict of interest All authors declare no competing interests.

Ethical approval The study was approved by the Ethical Review Board, Stockholm, Sweden.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Burstein HJ, ., Seidenfeld J, Prestrud A et al (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796
2. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816
3. Goss PE, Ingle JN, Pritchard KD et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219
4. McCowan C, Wang S, Thompson AM et al (2013) The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 109(5):1172–1180
5. Chirgwin JH, Giobbie-Hurder A, Coates AS et al (2016) Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, alone and in sequence. J Clin Oncol. https://doi.org/10.1200/JCO.2015.63.8619
6. Murphy CC, Bartholomew LK, Carpenter MY et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478
7. Farias AJ, Du XL (2017) Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer. J Clin Oncol 35(1):86–95
8. Ayres LR, Baldoni ADO, De Sá Borges AP, Pereira LRL (2014) Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm 36(1):45–54
9. He W, Fang G, Varnum C et al (2015) Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol 33(20):2262–2269
10. Wigeritz A, Ahlgren J, Holmqvist M et al (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: A population-based study. Breast Cancer Res Treat 133(1):367–373
11. World Health Organisation (2003) Adherence to long-term therapies: evidence for action. WHO, Geneva
12. Lundgren C, Lindman H, Rolander B, Ekholm M (2018) Good adherence to adjuvant endocrine therapy in early breast cancer—a population-based study based on the Swedish Prescribed Drug Register. Acta Oncol https://doi.org/10.1080/0284186X.2018.1442932
13. Charlson ME, Pompei P, Ales KL, MacKenzie R (1987) A new method of classifying prognostic prognostic in longitudinal studies: development and validation. J Chronic Dis 40:373–383
14. Llarena NC, Estevez SL, Tucker SL, Jeruss JS (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 107(10):1–9
15. Nabiieva N, Kellner S, Fehm T et al (2017) Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer. Ann Oncol Off J Eur Soc Med Oncol. https://doi.org/10.1093/annonc/mdx630
16. Calip GS, Xing S, Jun D-H et al (2017) Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer. J Oncol Pract 13(5):e451–e462
17. Neugut AI, Zhong X, Wright JD et al (2016) Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.1291
18. Sestak I, Cuzick J, Sapunar F et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872
19. Sestak I, Kealy R, Edwards R et al (2006) Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 24(24):3991–3996
20. Huiart L, Boughn A-D, Rey D et al (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer.
is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946
21. Hershman DL, Tsui J, Wright JD et al (2015) Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol 33(9):1053–1059
22. Lin JH, Zhang SM, Manson JE (2011) Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res 4(9):1360–1365
23. Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125(1):191–200
24. Socialstyrelsen (2011) Quality and efficiency in Swedish Cancer Care. Regional comparisons, 2011. Stockholm, Ordförrådet AB.
25. National Breast Cancer Quality Register (NKBC). http://statistik. incanet.se/brostcancer/
26. Feldman-Stewart D, Madaras Y, Mates M et al (2013) Information needs of post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy. Patient Educ Couns 93(1):114–121
27. Hershman DL, Kushi LH, Hillyer GC et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 157(1):1–11
28. Beryl LL, Rendle KAS, Halley MC et al (2017) Mapping the decision-making process for adjuvant endocrine therapy for breast cancer: the role of decisional resolve. Med Decis Making 37(1):79–90
29. Hurtado-de-Mendoza A, Cabling ML, Lobo T et al (2016) Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review. Clin. Breast Cancer 16(4):247–255
30. Lam WY, Fresco P (2015) Medication adherence measures: an overview. Biomed Res Int. https://doi.org/10.1155/2015/217047
31. Liu H, Golin CE, Miller LG et al (2001) A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 134(10):968–977
32. Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86(4):304–314